Study to assess the preventive effect of new probiotic strain on lactational mastitis.

- Healthy pregnant, adults (> 18 years of age);
- Before/during the 35th week of pregnancy;
- Intending to breastfeed her infant;
- Written informed consent.

- Pre-gravid body mass index (BMI)<18 or >30;
- Use of probiotic supplements during the third trimester of current pregnancy;
- Enhanced chance of premature delivery (before 37 weeks of gestation);
- Current or previous illnesses which could interfere with the study, like other mammary pathologies (e.g. abscesses, Raynaud¡¯s syndrome, breast cancer);
- Short bowel syndrome;
- Impaired intestinal epithelial barrier (e.g. diarrheal illness, intestinal inflammation);
- Serious underlying disease predisposing to infection (e.g. HIV, auto-immune diabetes, multiple organ failure, malignancy, severe burns, severe acute pancreatitis);
- Heart failure and cardiac medical history (e.g artificial heart valve, medical history of infectious endocarditis, rheumatic fever and cardiac malformation);
- History of aggressive immunosuppressive therapy (e.g. radiotherapy, cancer chemotherapy);
- Traumatic injury of the gastro-intestinal tract;
- Surgery, including dental surgery, within one month prior to inclusion (V1) ;
- Investigator's uncertainty about the willingness/ability of the subject to comply with protocol requirements;
- Participation in any other clinical trial within two weeks prior to entry into the study.